Melanocyte-inhibiting factor
Chemical compound
From Wikipedia, the free encyclopedia
Melanocyte-inhibiting factor (also known as Pro-Leu-Gly-NH2, melanostatin, MSH release–inhibiting hormone, or MIF-1) is an endogenous peptide fragment derived from cleavage of the hormone oxytocin, but having generally different actions in the body.[1][2] MIF-1 produces multiple effects, both blocking the effects of opioid receptor activation,[3][4][5][6][7][8] while at the same time acting as a positive allosteric modulator of the D2 and D4 dopamine receptor subtypes,[9][10][11][12][13][14][15][16][17] as well as inhibiting release of other neuropeptides such as alpha-MSH,[18][19][20] and potentiating melatonin activity.[21]
| Clinical data | |
|---|---|
| MedlinePlus | a605038 |
| Routes of administration | IV |
| Pharmacokinetic data | |
| Bioavailability | 100% (injected) |
| Metabolism | plasma protease enzymes |
| Excretion | N/A |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.016.276 |
| Chemical and physical data | |
| Formula | C13H24N4O3 |
| Molar mass | 284.360 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
This complex mix of actions produces a profile of antidepressant,[22][23][24] nootropic,[25][26][27][28] and anti-Parkinsonian effects when MIF-1 is administered,[29][30][31] and it has been investigated for various medical uses. MIF-1 is unusually resistant to metabolism in the bloodstream,[32] and crosses the blood–brain barrier easily,[33][34] though it is poorly active orally and is usually injected. Several other closely related peptides with important actions in the body include Tyr-MIF-1 and endomorphin-1 and -2.[35][36][37][38][39]
See also
- Nemifitide
- Doreptide